Acute Lymphoid Leukemia
Acute Lymphoid Leukemia (ALL)
Acute Lymphoblastic Leukemia (ALL), also known as acute lymphoid or lymphocytic leukemia, is a fast-growing cancer of the blood and bone marrow. It occurs when the body overproduces immature white blood cells, called lymphoblasts, which crowd out healthy red blood cells, platelets, and normal white blood cells.
When You Should Consider ALL Evaluation
Persistent fatigue or weakness due to low red blood cell counts.
Frequent or unexplained fevers and infections.
Easy bruising, frequent nosebleeds, or tiny red spots under the skin (petechiae).
Bone or joint pain caused by the buildup of lymphoblasts.
Swelling in the neck, armpits, or groin (lymph nodes) or a mass in the chest.
Methods of ALL Classification
B-cell ALL: The most common form, accounting for about 85% of childhood cases and 75–80% of adult cases.
T-cell ALL: More common in adults (25%) and often associated with a mediastinal (chest) mass.
Philadelphia Chromosome-Positive (Ph+ ALL): A high-risk subtype involving a specific genetic translocation that requires specialized targeted therapy.
How ALL Treatment Is Performed
Induction Therapy: Intensive chemotherapy lasting 4–6 weeks aimed at killing most cancer cells to achieve remission.
CNS-Directed Therapy: Intrathecal chemotherapy injected into spinal fluid to prevent cancer from hiding in the brain or spinal cord.
Consolidation Therapy: High-dose therapy lasting 6–8 months to destroy any remaining "hidden" cells after remission.
Maintenance Therapy: Lower-dose oral and IV drugs administered over 2–3 years to prevent the cancer from returning.
Advanced Options: Includes Targeted Therapy (blocking specific enzymes), Immunotherapy (monoclonal antibodies), and CAR T-cell Therapy (genetically modified T-cells).
Pre-Procedure Preparation
Detailed genetic testing and chromosomal analysis to identify specific ALL subtypes like Ph+.
Placement of a central venous catheter (port) to facilitate long-term chemotherapy and blood draws.
Discussion of fertility preservation options before starting intensive chemotherapy or radiation.
Baseline heart and lung function tests to ensure the body can tolerate intensive induction therapy.
Tests Before ALL Treatment
Bone Marrow Aspiration and Biopsy: To confirm the percentage of lymphoblasts in the marrow.
Lumbar Puncture (Spinal Tap): To check if leukemia cells have spread to the central nervous system.
Complete Blood Count (CBC): To evaluate the levels of red cells, white cells, and platelets.
Flow Cytometry: To determine the exact immunophenotype (B-cell vs. T-cell) of the leukemia cells.
Life After ALL Treatment
Children (Ages 1–10) see the best prognosis, with 5-year survival rates exceeding 90%.
Adolescents and young adults have an estimated 5-year survival rate of roughly 65–75%.
Regular follow-up for 2 to 3 years is required during the maintenance phase to monitor for relapse.
Long-term monitoring for "late effects" of treatment, such as cardiac issues or secondary cancers.
Benefits of ALL Treatment
Achieves high rates of complete remission through structured therapy phases.
Prevents central nervous system involvement through proactive CNS-directed treatments.
Offers curative potential for relapsed cases using modern advances like CAR T-cell therapy.
Restores normal bone marrow function and healthy blood cell production.
